Follow-on biologics hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
|Format:||Government Document Online Book|
|Series:||S. hrg. ;
|Online Access:||ONLINE VERSION|
No Tags, Be the first to tag this record!
|Item Description:||Title from title screen (viewed on Nov. 17, 2008).|
|Physical Description:||1 electronic text (iv, 78 p.) : HTML, digital, PDF file.|
|Format:||Mode of access: Internet from the GPO Access web site. Addresses as of 11/17/08: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.wais (text version); http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.pdf (PDF version) ; current access is available via PURLs.|
|Bibliography:||Includes bibliographical references.|